Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation

被引：3
|
作者：
Wood, Brian R. [1 ]
Kassaye, Seble G. [2 ]
Gerstoft, Jan [3 ]
机构：
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA USA
[2] Georgetown Univ, Dept Med, Washington, DC USA
[3] Univ Copenhagen, Dept Infect Dis, Rigshosp, Copenhagen, Denmark
来源：
AIDS | 2023年 / 37卷 / 04期
关键词：
RILPIVIRINE; FAILURE;
D O I：
10.1097/QAD.0000000000003476
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：689 / 691
页数：3
相关论文
共 50 条
  • [1] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
    Swindells, Susan
    Andrade-Villanueva, Jaime-Federico
    Richmond, Gary J.
    Rizzardini, Giuliano
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Pokrovsky, Vadim
    Bredeek, Fritz
    Smith, Graham
    Cahn, Pedro
    Kim, Yeon-Sook
    Ford, Susan L.
    Talarico, Christine L.
    Patel, Parul
    Chounta, Vasiliki
    Crauwels, Herta
    Parys, Wim
    Vanveggel, Simon
    Mrus, Joseph
    Huang, Jenny
    Harrington, Conn M.
    Hudson, Krischan J.
    Margolis, David A.
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1112 - 1123
  • [2] COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN
    Wen, Y. C.
    Ou, H. T.
    Tien, K.
    Harrison, C.
    Omonmhenle, D.
    Turner, M.
    Anderson, S. J.
    Jacob, I
    VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
  • [3] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
    Chan, M. C. J.
    Chik, S. H. T.
    Lamb, S. S.
    Choi, Y. C. C.
    Lau, W. T. A.
    Leung, C. S. E.
    To, P. Y. L.
    Lau, P. L. D.
    Tsang, T. Y. O.
    HIV MEDICINE, 2023, 24 : 155 - 156
  • [4] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
    Orkin, Chloe O. C.
    Arasteh, Keikawus A. K.
    Hernandez-Mora, M. Gorgolas M. G. H. M.
    Pokrovsky, Vadim P. V.
    Overton, Edgar T. O. E. T.
    Girard, Pierre-Marie G. P. M.
    Oka, Shinichi O. S.
    Walmsley, Sharon W. S.
    Bettacchi, Chris B. C.
    Brinson, Cynthia B. C.
    Philibert, Patrick P. P.
    Lombaard, Johan L. J.
    Clair, Marty C. M.
    Crauwels, Herta C. H.
    Ford, Susan L. F. S. L.
    Patel, Parul P. P.
    Chounta, Vasiliki C. V.
    D'Amico, Ronald D. R.
    Vanveggel, Simon V. S.
    Dorey, David D. D.
    Cutrell, Amy C. A.
    Griffith, Sandy G. S.
    Margolis, David A. M. D. A.
    Williams, Peter E. W. P. E.
    Parys, Wim P. W.
    Smith, Kimberly Y. S. K. Y.
    Spreen, William R. S. W. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
  • [5] Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
    Iannone, Valentina
    Rossotti, Roberto
    Bana, Nicholas Brian
    Cavazza, Gabriele
    D'Amico, Federico
    Lombardi, Francesca
    Salvo, Pierluigi Francesco
    Baldin, Gianmaria
    Di Giambenedetto, Simona
    Bernacchia, Dario
    Pagani, Gabriele
    Borghetti, Alberto
    Rusconi, Stefano
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [6] Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative
    Derrick, Caroline B.
    Magee, Matthew
    Tsai, Y. Vivian
    Pizzuti, Morgan E.
    Parker, Sarah
    Lucas, Omar
    Taylor, Kara
    Albright, Raeghan
    Langehans, Briley
    Schreiber, Danny
    Guest, Georgia
    Ahuja, Divya
    Weissman, Sharon
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024,
  • [7] Long-acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real-world study (RELATIVITY cohort)
    Troya, Jesus
    Morano, Luis
    Ignacio Bernardino, Jose
    Buzon Martin, Luis
    Pedrero Tome, Roberto
    Galindo Puerto, Maria Jose
    Torralba, Miguel
    Cabello Clotet, Noemi
    Garcia Lopez, Maria
    Lope, Silvia
    de Zarraga Fernandez, Miguel Alberto
    Cabello, Alfonso
    Aguilera Garcia, Maria
    Cecilio, Alvaro
    Diaz de Santiago, Alberto
    Garcinuno Jimenez, Maria Angeles
    Bernal, Enrique
    Lopez Caballero, Maria Teresa
    Calderon Hernaiz, Ruth
    Vivancos Gallego, Maria Jesus
    Omiste Sanvicente, Teresa
    Ferreira Pasos, Eva
    Losa Garcia, Juan Emilio
    Soler Gonzalez, Josefa Francisca
    Antonia Sepulveda, Maria
    Garcia Navarro, Maria del Mar
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 92 - 93
  • [8] REAL-WORLD PRESCRIBING OF LONG-ACTING INJECTABLE CABOTEGRAVIR FOR TREATMENT OF HIV IN THE UNITED STATES
    Rodriguez, P.
    Cartwright, B.
    Gratzl, S.
    Stucky, N.
    VALUE IN HEALTH, 2023, 26 (12) : S304 - S304
  • [9] Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
    Michael G. Sension
    Laurence Brunet
    Ricky K. Hsu
    Jennifer S. Fusco
    Quateka Cochran
    Christine Uranaka
    Gayathri Sridhar
    Vani Vannappagari
    Jean Van Wyk
    Lewis McCurdy
    Michael B. Wohlfeiler
    Gregory P. Fusco
    Infectious Diseases and Therapy, 2023, 12 : 2807 - 2817
  • [10] Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection
    Durham, Spencer H.
    Chahine, Elias B.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (11) : 1397 - 1409
12345